NanovelosS.A.
Research and experimental development in natural sciences and engineering
Overview
Nanovelos is a biotechnology company specializing in the use of nanotechnology for oncological therapies. It develops polysaccharide-based drug carriers aimed at precise drug delivery for cancer treatment, specifically working on an effective drug using epirubicin (PolEpi) for ovarian cancer therapy. The company's technology aims to enhance treatment efficacy while minimizing adverse effects on patients.
Financials
Revenue history (in k)
Financial insight
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 — this may be an accounting template or the first year of the regime.
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2013-04-25. Active
88 1090 1056 0000 0001 2050 0979- 54 1090 1056 0000 0001 4676 5214
- 14 1090 1056 0000 0001 3508 2090
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jul 2, 2018 | Call to creditors |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,930 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,841 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,751 | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2016-06-01 | Badania przedkliniczne i kliniczne innowacyjnych nanoformulacji leków przeciwnowotworowych. | $2,480,610 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
In the case of a one-person management board, the President of the Management Board is authorized to make declarations of will on behalf of the company and to represent the company. If a multi-member management board is appointed, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to perform legal acts and make declarations on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Tomasz Adam Ciach (61)  | Natural person holding a senior management position in a parent entity (e.g. parent company). |
Przemysław Daniel Mazurek (50) | Natural person holding a senior management position in a parent entity (e.g. parent company). |
Piotr Paweł Mierzejewski (62) | Natural person holding a senior management position in a parent entity (e.g. parent company). |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| Sfpesp. z o.o. | $72,850.26 | sfpe.co.pl | |
| Luna Laboratorysp. z o.o. | $61,894.23 | lunalab.pl | |
| Receptonsp. z o.o. | $50,611.05 | receptonbiotech.com | |
| Zawamedsp. z o.o. | $43,909.06 | zawamed.pl | |
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | |
| CadenasP.S.A. | $31,138.51 | cadenas.tech | |
| CannamedaiS.A. | $28,203.90 | cannamedai.com | |
| Medaisp. z o.o. | $22,311.83 | medai.pl | |
| 4cell TherapiesS.A. | $9,123.06 | 4celltherapies.com | |
| Oncotherics PolandS.A. | $7,565.33 | oncotherics.com |
Change history
| Date | Event |
|---|---|
| 2025-10-31 | PKD change (Removed: 70.22.Z, 71.12.Z, 71.20, 71.20.B, 72.11.Z, 72.19.Z, 74.90.Z; Added: 70.20.Z, 71.12.B, 71.20.C, 72.10.Z, 74.91) |
| 2025-01-24 | Share capital change (981,537.50 PLN → 1,004,320.80 PLN) |
| 2023-11-14 | Share capital change (681,537.50 PLN → 981,537.50 PLN) |
| 2023-06-12 | Share capital change (181,537.50 PLN → 681,537.50 PLN) |
| 2022-12-07 | Share capital change (178,720.50 PLN → 181,537.50 PLN) |
FAQ
Last updated: 2026-07-17